HC Deb 21 April 2004 vol 420 cc548-9W
Mr. Burstow

To ask the Secretary of State for Health what work is being undertaken by the National Institute for Clinical Excellence into the most efficient use of blood donations in the NHS. [163565]

Miss Melanie Johnson

Erythropoietin for the treatment of chemotherapy induced anaemia, as an alternative to blood transfusion, was referred to the National Institute for Clinical Excellence (NICE) as part of the ninth wave work programme in October 2003. Full details of the technology appraisal can be found on NICE's website at www.nice.org.uk. No other topics on alternatives to blood transfusion are planned for referral to NICE at this time.

Mr. Burstow

To ask the Secretary of State for Health upon what evidence his Department based its position that there is less risk of variant CJD infection via blood transfusions of pooled plasma than via blood transfusions from one blood donor. [163472]

Miss Melanie Johnson

A paper by Llewelyn CA. et al (2004);Lancet; Vol. 363, pp 417–421 reported that the risks from products prepared from large pools of plasma to a recipient are probably less than from blood transfusion. The paper has been placed in the Library. The lower individual risk is also indicated by the risk assessment carried out by Det Norske Veritas.